Skip to content
Bored Studies
RecruitingPhase 1

OM336 in Autoimmune Cytopenias

Lakefront Biotherapeutics West LLC · NCT07083960

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
32
US sites recruiting
4
Study start
August 1, 2025
Record last updated
September 3, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

Being studied: OM336

Conditions: AIHA - Warm Autoimmune Hemolytic Anemia; AIHA - Cold Autoimmune Hemolytic Anemia; ITP - Immune Thrombocytopenia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Active autoimmune cytopenia
  • Relapsed/refractory after ≥1 prior treatment
  • Body weight ≥ 55 kg
  • Willing to comply with and study requirements and procedures

Key Exclusion Criteria

  • Previous treatment with a BCMA-targeted therapy
  • Clinically significant infection within 3 months of screening
  • Major surgery or splenectomy within 3 months of screening or planned during the study
  • Pregnant or breastfeeding

Recruiting US locations

  • City of Hope

    Duarte, CA 91010

    Site contact: Primary Contact · (888) 734-0917 · shhussain@coh.org

  • Medstar

    Washington D.C., DC 20007

    Site contact: Primary Contact · 202-444-2000 · jacobsh@georgetown.edu

  • University of Michigan

    Ann Arbor, MI 48109

    Site contact: Primary Contact · 734-764-1817 · jreginal@med.umich.edu

  • Fred Hutchinson Cancer Center

    Seattle, WA 98109

    Site contact: Primary Contact · 855-557-0555 · Milleris@fredhutch.org

Study contacts (from the official record)

  • Study Sponsor · 415-429-4887 · clinicaltrials@lakefrontbio.com
All phase 1 studies in California →
OM336 in Autoimmune Cytopenias (NCT07083960) | Bored Studies